Are drugs in space for real this time? Varda Space Industries, which just announced they had raised $137 million to start industrializing bio-processing in low-earth orbit, certainly thinks so. Endpoints Executive Editor Drew Armstrong and Senior Science Correspondent Ryan Cross are more skeptical — so Varda’s Chief Science Officer Adrian Radocea is joining Post-Hoc Live to try and convince them that it’s not just hype. They’ll talk about microgravity chemistry, experiments in orbit, and what Varda plans to do with its new influx of cash.

Ver todos los episodios